Literature DB >> 22849699

Regenerative treatment in spinal cord injury.

Mevci Ozdemir1, Ayhan Attar, Isinsu Kuzu.   

Abstract

Spinal cord injury is a devastating, traumatic event, and experienced mainly among young people. Until the modern era, spinal cord injury was so rapidly fatal that no seriously injured persons would survive long enough for regeneration to occur. Treatment of spinal cord injury can be summarized as follows: prevent further cord injury, maintain blood flow, relieve spinal cord compression, and provide secure vertebral stabilization so as to allow mobilization and rehabilitation, none of which achieves functional recovery. Previous studies have focused on analyzing the pathogenesis of secondary injury that extends from the injury epicenter to the periphery, as well as the tissue damage and neural cell death associated with secondary injury. Now, there are hundreds of current experimental and clinical regenerative treatment studies. One of the most popular treatment method is cell transplantation in injured spinal cord. For this purpose bone marrow stromal cells, mononuclear stem cells, mesenchymal stem cells, embryonic stem cells, neural stem cells, and olfactory ensheathing cells can be used. As a result, cell transplantation has become a promising therapeutic option for spinal cord injury patients. In this paper we discuss the effectiveness of stem cell therapy in spinal cord injury.

Entities:  

Mesh:

Year:  2012        PMID: 22849699     DOI: 10.2174/157488812802481481

Source DB:  PubMed          Journal:  Curr Stem Cell Res Ther        ISSN: 1574-888X            Impact factor:   3.828


  9 in total

1.  Epidemiology of traumatic spinal cord injury in Tianjin, China: An 18-year retrospective study of 735 cases.

Authors:  Hai-Liang Li; Hong Xu; Yu-Lin Li; Shi-Wei Sun; Wen-Ye Song; Qiang Wu; Jie Ai; Jing-Cheng Sun; Guang-Zhi Ning; Shi-Qing Feng
Journal:  J Spinal Cord Med       Date:  2018-01-11       Impact factor: 1.985

2.  Administration of antagomir-223 inhibits apoptosis, promotes angiogenesis and functional recovery in rats with spinal cord injury.

Authors:  Da Liu; Ying Huang; Changqing Jia; Yan Li; Feng Liang; Qin Fu
Journal:  Cell Mol Neurobiol       Date:  2014-11-22       Impact factor: 5.046

3.  Protective role of microRNA-219-5p inhibitor against spinal cord injury via liver receptor homolog-1/Wnt/β-catenin signaling pathway regulation.

Authors:  Jie Li; Liqiang Li; Yong Shen
Journal:  Exp Ther Med       Date:  2018-02-01       Impact factor: 2.447

Review 4.  Receptor for advanced glycation end products (RAGE) and its ligands: focus on spinal cord injury.

Authors:  Juhyun Song; Won Taek Lee; Kyung Ah Park; Jong Eun Lee
Journal:  Int J Mol Sci       Date:  2014-07-25       Impact factor: 5.923

5.  Ecto-domain phosphorylation promotes functional recovery from spinal cord injury.

Authors:  Kenji Suehiro; Yuka Nakamura; Shuai Xu; Youichi Uda; Takafumi Matsumura; Yoshiaki Yamaguchi; Hitoshi Okamura; Toshihide Yamashita; Yoshinori Takei
Journal:  Sci Rep       Date:  2014-05-15       Impact factor: 4.379

6.  Ursolic acid induces neural regeneration after sciatic nerve injury.

Authors:  Biao Liu; Yan Liu; Guang Yang; Zemin Xu; Jiajun Chen
Journal:  Neural Regen Res       Date:  2013-09-25       Impact factor: 5.135

7.  Propofol's effect on the sciatic nerve: Harmful or protective?

Authors:  Yi Sun; Xizhe Zhang; Qi Zhou; Yong'an Wang; Yiwen Jiang; Jian Cao
Journal:  Neural Regen Res       Date:  2013-09-25       Impact factor: 5.135

8.  Curcumin upregulates S100 expression and improves regeneration of the sciatic nerve following its complete amputation in mice.

Authors:  Guo-Min Liu; Kun Xu; Juan Li; Yun-Gang Luo
Journal:  Neural Regen Res       Date:  2016-08       Impact factor: 5.135

9.  Oligodendrocyte precursor cell transplantation promotes functional recovery following contusive spinal cord injury in rats and is associated with altered microRNA expression.

Authors:  Jin Yang; Liu-Lin Xiong; You-Cui Wang; Xiang He; Ling Jiang; Song-Jun Fu; Xue-Fei Han; Jia Liu; Ting-Hua Wang
Journal:  Mol Med Rep       Date:  2017-11-03       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.